Henry Schein Acquires Majority Stake in Biotech Dental

English

简体中文 繁體中文 English Filipino हिन्दी Hmong Bahasa Indonesia 日本語 Basa Jawa 한국어 ພາສາລາວ Bahasa Melayu മലയാളം ဗမာစာ سنڌي தமிழ் ไทย Tiếng Việt Afrikaans Shqip العربية አማርኛ Հայերեն Azərbaycan dili Euskara Беларуская мова বাংলা Bosanski Български Català Cebuano Chichewa Corsu Italiano Hrvatski Čeština‎ Dansk Nederlands Esperanto Eesti Suomi Frysk Galego ქართული Ελληνικά ગુજરાતી Kreyol ayisyen Deutsch Français Harshen Hausa Ōlelo Hawaiʻi עִבְרִית Magyar Íslenska Igbo Gaeilge ಕನ್ನಡ Қазақ тілі ភាសាខ្មែរ كوردی‎ Кыргызча Latin Latviešu valoda Lietuvių kalba Lëtzebuergesch Македонски јазик Malagasy Maltese Te Reo Māori मराठी Монгол नेपाली Norsk bokmål پښتو فارسی Polski Português ਪੰਜਾਬੀ Română Русский Samoan Gàidhlig Српски језик Sesotho Shona සිංහල Slovenčina Slovenščina Afsoomaali Español Basa Sunda Kiswahili Svenska Тоҷикӣ తెలుగు Türkçe Українська اردو O‘zbekcha Cymraeg isiXhosa יידיש Yorùbá Zulu

Global healthcare solutions provider, Henry Schein, has completed the acquisition of a majority ownership stake in Biotech Dental. The France-based company specialises in dental implants, clear aligners and digital dental software. 

Biotech Dental’s Nemotec is an integrated suite of planning and diagnostic software, which uses open architecture to connect disparate medical devices and create a digital view of the patient. The company’s offerings also include custom abutments and implants under the Kontact brand, clear aligners under the Smilers brand, and LaGalaxy, an open and secure software platform for clinical and administrative tasks.

Streamlining Clinical and Administrative Workflows

Henry Schein aims to bring Biotech Dental‘s software products to its customers to create a digital workflow that provides a seamless journey, streamlining the clinical as well as administrative workflow for the ultimate benefit of patients. Under the agreement, Biotech Dental maintains its own brands and go-to-market strategies.

Philippe Veran, Biotech Dental founder and President, remains in charge of the business. He said, “This investment marks a new chapter for our customers, who will benefit from the innovation and new technologies we will bring to the global dental community as well as access to a wide array of products and services available through Henry Schein.”

Financial terms of the transaction were not disclosed. The company brought in revenues of approximately $100 million in 2022. Henry Schein expects a slightly dilutive impact on its 2023 earnings per share as a result of the transaction.

Under the terms of the deal, both Philippe and Olivia Veran, the respective President and SVP of Biotech, become minority partners in Henry Schein Orthodontics, which enables the companies to offer a best-in-class, comprehensive set of orthodontic solutions to a combined customer base.